Table 6.
Status of monoclonal antibodies in 2009 [147].
| mAb species origin | Number of mAb products (fraction) | |||||
|---|---|---|---|---|---|---|
| Of total | In marketa |
Withdrawn from market |
In preclinical or clinical trials |
Radiolabeled mAbsb | ||
| In | Withdrawn | |||||
| Murine | 36/242 | 7/36 | 8/36 | 21/36 | 3/7 | 7/8 |
| Chimericc | 24/242 | 11/24 | 0/24 | 13/24 | 0/11 | 0/0 |
| Humanizedd | 127/242 | 12/127 | 1/127 | 114/127 | 0/12 | 1/1 |
| Human | 55/242 | 2/55 | 2/55 | 51/55 | 0/2 | 1/2 |
aAchieved market authorization and commercially available; bdiagnostic and therapy radioisotopes; cstructure contains one species other than human; dstructure contains variable chains not human.